Suven Life Sciences has secured 3 product patents for its New Chemical Entities (NCEs), one product patent from South Korea, one product patent from China and one product patent from Canada corresponding to the NCEs for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2029, 2029 and 2031 respectively.
Real Time News & Trading Trends Keep Liking #EpicResearch
Facebook – Twitter – YouTube – Pinterest –Linkedin - Google+
For more information ✆ – 0731-6642300 or Visit http://ift.tt/1k8NnLH
0 comments:
Post a Comment